Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.001 par value CRVO NASDAQ Capital Market May 15, 2024 Date of Report (Date of earliest event reported) 20 Park Plaza, Suite 424 Boston, Massachusetts 02116 (Address of principal executive offices) (Zip Code) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Pre-commencement communications p ...

BOSTON, May 15, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ:CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today reported its financial results for the first quarter ended March 31, 2024. "Building on a year of high operational and clinical achievement, already in 2024, we have strengthened our financial resources and published data that further positions our lead clinical program, neflamapimod, as a highly differentiated, potential first-to-market ...

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 CervoMed Inc. Condensed Consolidated Statements of Operations (unaudited) The fair value of the 2020 Notes and the 2021 Notes, and collectively the Convertible Notes (Note 7) as of March 31, 2023 were estimated as the combination of a zero-coupon bond and a call option. The combined values for each of the 2020 Notes and the 2021 Notes as of March 31, 2023 were then weighted by the probability of completing a financing ...

Jacob Wackerhausen/iStock via Getty Images CervoMed (NASDAQ:CRVO) has been enrolling for its phase 2b RewinD-LB study, which is using neflamapimod for the treatment of patients with dementia with Lewy bodies [DLB]. The reason to note this biotech is that it had stated that it is on track to complete enrollment of this trial in the 1st half of 2024. Not only that but from there, it is said that it will be able to release results from this phase 2b study in the 2nd half of 2024. This is going to be a major in ...

(Mark one) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to (Exact Name of Registrant as specified in its Charter) (617) 744-4400 (Registrant's telephone number, including area code) Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the ...

- Neflamapimod led to significant reduction compared to placebo in plasma levels of glial fibrillary acidic protein (GFAP) - Neflamapimod effects on GFAP correlated to clinical outcomes assessed by CDR Sum of Boxes (CDR-SB) - Scientific collaborators from University College London (UCL) present data demonstrating neflamapimod improves axonal transport in a transgenic mouse model of frontotemporal dementia (FTD) BOSTON, March 05, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ:CRVO), a clinical stage company ...

Dr. Boger is the founder, and retired CEO and Board Chair, of Vertex Pharmaceuticals CervoMed on track to complete enrollment in 1H 2024 in its RewinD-LB Phase 2b clinical trial evaluating neflamapimod in patients with dementia with Lewy bodies; topline data expected in 2H 2024 BOSTON, Feb. 07, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ:CRVO), a clinical-stage company developing treatments for degenerative diseases of the brain, today announced the appointment of Joshua Boger, Ph.D., to its Board of Dir ...

BOSTON, Feb. 05, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ:CRVO), a clinical stage company focused on developing treatments for degenerative diseases of the brain, today announced that Company's Management will provide a corporate update at the Emerging Growth Conference 67, to be held virtually from February 7-8, 2024. Presentation Details Format: Corporate presentation Date: Wednesday, February 7, 2024Time: 3:50 PM ETRegistration Link: click here A live webcast of the presentation, along with accompa ...

Financial Performance - Grant revenue for the three months ended September 30, 2023, was $1,526,482, compared to $0 for the same period in 2022[318]. - The net income for the three months ended September 30, 2023, was $2,150,362, compared to a net loss of $882,623 for the same period in 2022[318]. - The company reported a net income of $190,525 for the nine months ended September 30, 2023, compared to a net loss of $4,275,647 for the same period in 2022[364]. - The adjusted net income (loss) for the nine months ended September 30, 2023, was $(5,233,726), compared to $(4,275,647) for the same period in 2022[393]. - Net income per share of common stock (basic) for the three months ended September 30, 2023, was $0.65, compared to a loss of $1.70 for the same period in 2022[318]. Operating Expenses - Total operating expenses for the nine months ended September 30, 2023, were $9,986,739, a significant increase from $2,536,711 in the same period of 2022[318]. - Research and development expenses for the nine months ended September 30, 2023, totaled $5,583,149, up from $955,784 in the same period of 2022[318]. - General and administrative expenses for the three months ended September 30, 2023, were $2,410,124, compared to $573,511 for the same period in 2022[318]. - The loss from operations for the nine months ended September 30, 2023, was $(5,332,445), compared to a loss of $(2,536,711) in the same period of 2022[318]. Stock and Equity - The weighted average shares outstanding for basic net income per share was 3,308,302 for the three months ended September 30, 2023, compared to 518,140 for the same period in 2022[318]. - The company underwent a reverse stock split at a ratio of 1-for-1.5 on August 16, 2023, affecting the common stock structure[306]. - The total number of shares of the Company's common stock outstanding immediately after the Merger was approximately 5,674,277[444]. - The company issued 795,905 shares of common stock and 101,367 pre-funded warrants upon the settlement of Convertible Notes as part of the merger[458]. Grants and Funding - The company was awarded a $21.0 million grant from the NIA in January 2023 to support its ongoing Phase 2b study of neflamapimod, expected to be received over three years[366]. - Total revenue recognized from the National Institute of Aging (NIA) grant was $1.6 million and $4.7 million for the three and nine months ended September 30, 2023, respectively[425]. - As of September 30, 2023, total cash funding of $5.2 million has been received from the NIA grant, with approximately $15.8 million in funding remaining[425]. Clinical Development - The company is currently developing neflamapimod, an investigational drug for treating degenerative brain diseases, and is in a Phase 2b clinical trial for patients with DLB[341]. - The ongoing Phase 2b clinical trial for neflamapimod is expected to complete enrollment in the first half of 2024, with initial results anticipated in the second half of 2024[1]. - Neflamapimod has shown statistically significant improvement in dementia severity (p=0.023) and motor function (p=0.044) in a Phase 2a clinical trial[1]. - The success of the ongoing Phase 2b clinical trial is essential for the company's future revenue projections and market acceptance of its product candidates[328]. Financial Position - As of September 30, 2023, total stockholders' equity was reported at $9,574,200, a significant increase from a deficit of $33,285,059 at the end of 2022[333]. - The company reported an accumulated deficit of $52,078,391 as of September 30, 2023, a slight improvement from $52,268,916 at the end of 2022[333]. - The company has a total liability of $12,414,000 in convertible notes as of September 30, 2023, unchanged from the previous year[352]. - The company anticipates requiring additional financing to support clinical development and operations in the foreseeable future[343]. Cash Flow and Financing - As of September 30, 2023, the company has cash and cash equivalents totaling $10,424,675, an increase from $4,093,579 at the end of 2022[350][364]. - The company raised $810,000 from the sale of common stock during the nine months ended September 30, 2023[364]. - The company reported a significant increase in cash flow from financing activities, totaling $11,242,489 for the nine months ended September 30, 2023[364]. - The company plans to seek funds through equity offerings, debt financings, or other capital sources to support its business strategies[343]. Corporate Changes - On August 16, 2023, the merger between Diffusion Pharmaceuticals Inc. and EIP Pharmaceuticals, Inc. was completed, resulting in EIP becoming a wholly-owned subsidiary of the newly named CervoMed Inc.[324]. - The merger is treated as a reverse recapitalization under US GAAP, with EIP's historical results considered the Company's historical results prior to the merger[324]. - The company changed its corporate name from "Diffusion Pharmaceuticals Inc." to "CervoMed Inc." following the merger with EIP on August 16, 2023[365].

DIFFUSION PHARMACEUTICALS INC. The following table summarizes the activity related to all stock option grants for the six months ended June 30, 2023: There were no options granted during the six months ended June 30, 2023. The total fair value of options vested during the three months ended June 30, 2023 and 2022 was $0.1 million and $0.3 million, respectively. The total fair value of options vested during the six months ended June 30, 2023 and 2022 was $0.2 million and $0.5 million, respectively. No option ...